<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">Hypoalphalipoproteinemia</z:e> is the most common <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> abnormality in patients with <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, yet its causes are unknown </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: We show that the homozygous staggerer (sg/sg) mutant mouse, which carries a deletion within the nuclear receptor RORalpha gene, develops severe <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> when maintained on an atherogenic diet </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, sg/sg mice display a profound <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e>, which is associated with decreased plasma levels of the major <z:chebi fb="17" ids="39025">HDL</z:chebi> proteins, <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> (apo) A-I and apoA-II </plain></SENT>
<SENT sid="3" pm="."><plain>This decrease in <z:chebi fb="17" ids="39025">HDL</z:chebi> levels in sg/sg mice is due to lowered apoA-I gene expression in the intestine but not in the liver </plain></SENT>
<SENT sid="4" pm="."><plain>ApoA-II gene expression is unaffected </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: These results suggest that the RORalpha gene contributes to the plasma <z:chebi fb="17" ids="39025">HDL</z:chebi> level and susceptibility to <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
</text></document>